Y-mAbs Therapeutics Informs Participation in Key Investor Conferences
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a prominent player in the biopharmaceutical industry, is enthusiastic about its upcoming participation in significant investor conferences. These events are crucial for the company as they emphasize innovative developments in radioimmunotherapy and antibody-based treatments targeted at combating cancer.
Overview of Upcoming Conferences
The management team at Y-mAbs will be engaged in two noteworthy conferences on the very same day, aimed at exploring advanced therapeutic strategies in oncology.
Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit
On Tuesday, October 8, Y-mAbs will have a platform at the Oppenheimer Summit, scheduled to commence at 9:30 a.m. ET. This event is set to focus on the session "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes". Such discussions will delve into emerging trends and targeted therapies that may reshape the treatment landscape for cancer patients.
BMO Oncology Summit
Later on the same day, the company will transition to the BMO Oncology Summit, where a fireside chat titled "Shifting the Antibody Paradigm" will take place at 3:00 p.m. ET. This dialogue is anticipated to shed light on the evolving role of antibodies in oncological applications, showcasing Y-mAbs’ commitment to groundbreaking solutions in the fight against cancer.
About Y-mAbs and Their Innovative Approach
Y-mAbs Therapeutics specializes in the creation and commercial distribution of state-of-the-art therapeutic products primarily aimed at cancer treatment. Their innovative technology portfolio includes the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and unique bispecific antibodies produced via the Y-BiClone platform.
The company boasts a diverse and advanced pipeline of products, including DANYELZA® (naxitamab-gqgk), which has garnered FDA approval as the first treatment for patients battling relapsed or refractory high-risk neuroblastoma. This treatment showcases the company's commitment to providing effective solutions for pediatric patients facing tough prognoses.
Investor Relations and Contact Information
For those interested in the company's advancements or investor inquiries, Y-mAbs encourages reaching out to their investor relations team. Courtney Dugan, Vice President and Head of Investor Relations, is available for any inquiries related to business strategies, investor updates, and more.
Contact Information:
Courtney Dugan
VP, Head of Investor Relations
Email: cdu@ymabs.com
Frequently Asked Questions
What is Y-mAbs Therapeutics, Inc. known for?
Y-mAbs Therapeutics is known for its dedication to developing innovative therapies, especially in the field of cancer treatment through radioimmunotherapy and antibody-based approaches.
Why are the upcoming conferences important for Y-mAbs?
The conferences provide a platform for Y-mAbs to share insights on their advancements and engage with potential investors, enhancing visibility and opportunities in the industry.
What is DANYELZA® and its significance?
DANYELZA® is the first FDA-approved drug for treating relapsed or refractory high-risk neuroblastoma, highlighting Y-mAbs’ pivotal role in pediatric oncology.
Who can be contacted for investor inquiries?
Investors can contact Courtney Dugan, the VP of Investor Relations at Y-mAbs, via the provided email for any queries.
When will Y-mAbs participate in the investor conferences?
Y-mAbs will participate in the aforementioned conferences on October 8, where their management team will present and engage in discussions regarding their products and innovations.
